- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Positioning of proteasome inhibitors in therapy of solid malignancies ; volume:81 ; number:2 ; day:28 ; month:11 ; year:2017 ; pages:227-243 ; date:2.2018
Cancer chemotherapy and pharmacology ; 81, Heft 2 (28.11.2017), 227-243, 2.2018
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Roeten, Margot S. F.
- Beteiligte Personen und Organisationen
-
Cloos, Jacqueline
Jansen, Gerrit
SpringerLink (Online service)
- DOI
-
10.1007/s00280-017-3489-0
- URN
-
urn:nbn:de:1111-201803215785
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Roeten, Margot S. F.
- Cloos, Jacqueline
- Jansen, Gerrit
- SpringerLink (Online service)
Ähnliche Objekte (12)
Proteasome inhibitors against amelanotic melanoma
Gastrointestinal toxicities of proteasome inhibitor therapy
Checkpoint inhibitors in hematological malignancies
Characterisation and optimisation of 20S proteasome inhibitors
Characterisation and optimisation of 20S proteasome inhibitors
Targeting hypoxia in solid and haematological malignancies
Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
BU-32: a novel proteasome inhibitor for breast cancer
Patented small molecule inhibitors in the ubiquitin proteasome system
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Proteasome inhibitors against amelanotic melanoma
Gastrointestinal toxicities of proteasome inhibitor therapy
Checkpoint inhibitors in hematological malignancies
Characterisation and optimisation of 20S proteasome inhibitors
Characterisation and optimisation of 20S proteasome inhibitors
Targeting hypoxia in solid and haematological malignancies
Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
BU-32: a novel proteasome inhibitor for breast cancer
Patented small molecule inhibitors in the ubiquitin proteasome system
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Proteasome inhibitors against amelanotic melanoma
Gastrointestinal toxicities of proteasome inhibitor therapy
Checkpoint inhibitors in hematological malignancies
Characterisation and optimisation of 20S proteasome inhibitors
Characterisation and optimisation of 20S proteasome inhibitors
Targeting hypoxia in solid and haematological malignancies
Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
BU-32: a novel proteasome inhibitor for breast cancer
Patented small molecule inhibitors in the ubiquitin proteasome system